Grunenthal GmbH, founded in 1881 and headquartered in Aachen, Germany, is a global leader in the pharmaceutical industry, focused on developing innovative pain management solutions. The company's key products include a diverse range of medications and therapies aimed at improving quality of life for patients suffering from various pain conditions.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| GRUPHA 3.63% 2026-11-15 EURGrunenthal GmbH | Germany | 2026-11-15 | 3.625 | 3.48 |
| GRUPHA 3.63% 2026-11-15 EURGrunenthal GmbH | Germany | 2026-11-15 | 3.625 | 3.48 |
| GRUPHA 4.13% 2028-05-15 EURGrunenthal GmbH | Germany | 2028-05-15 | 4.125 | 4.18 |
| GRUPHA 4.13% 2028-05-15 EURGrunenthal GmbH | Germany | 2028-05-15 | 4.125 | 4.18 |
| GRUPHA 6.75% 2030-05-15 EURGrunenthal GmbH | Germany | 2030-05-15 | 6.750 | 5.56 |
| GRUPHA 6.75% 2030-05-15 EURGrunenthal GmbH | Germany | 2030-05-15 | 6.750 | 5.56 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Grunenthal GmbH began issuing bonds in 2003, showcasing its commitment to fund research and development in pain management. Notably, in 2019, the company issued €300 million in senior unsecured bonds, which received strong demand and significantly contributed to its growth strategy. Current bond yields are competitive within the industry, reflecting investor confidence in Grunenthal's stability and future prospects. The bonds are characterized by their favorable terms, including early redemption features, allowing flexibility for corporate actions in the future.